If a supplied lot fails agreed specifications, we’ll replace it at no cost or refund its purchase price in full.
Quality test failed? Free replacement or full refund.
Off-spec? Free replacement or full refund.
FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →
FDA PCAC reviews 7 peptides for the 503A bulks list in July. Read →
FDA PCAC: 7 peptides under review. Read →
Khavinson neuroprotective tripeptide (Glu-Asp-Arg, EDR)
Overview
Pinealon (Glu-Asp-Arg, EDR) is a synthetic tripeptide bioregulator developed by Vladimir Khavinson's team at the St. Petersburg Institute of Bioregulation and Gerontology in Russia. It belongs to the Khavinson family of short peptide bioregulators and traces its research lineage back to work on bovine brain polypeptide complexes (such as Cortexin). It is characterized by low molecular weight and some capacity for cell membrane penetration; research suggests it can interact directly with DNA/chromatin to regulate gene expression, with research focus concentrated on neuroprotection and cognitive function. Nearly all of the evidence base comes from Russian research groups, and independent replication in Western peer-reviewed literature is limited. Note: Cortexin itself is a bovine brain polypeptide extract (a first-generation "Cytomax"-class bioregulator), whereas Pinealon is a structurally defined synthetic short peptide (a second-generation "Cytogen"-class bioregulator) — the two share a research lineage but are different product types. Vialdyne releases Pinealon as a lyophilized tripeptide (linear) against a ≥99.0% HPLC main-peak specification, with a batch-specific Certificate of Analysis covering RP-HPLC purity and mass-spec identity; water content, residual solvents and endotoxin are available on request and listed on the COA when tested. Sequence / identity confirmation is documented on the released lot.
Applications & buyer fit
Cognitive and neuropeptide buyers are predominantly research labs running in vivo rodent studies. The dominant administration route in the literature is intranasal, these peptides are not meaningfully blood-brain-barrier permeable when delivered systemically. For in vivo workflows, endotoxin and microbial-limit testing is recommended at the COA stage so the bioassay readout is not confounded by contamination unrelated to the test article.
Sourced for
Buyer fit
Documentation that ships
Procurement note: For in vivo workflows, endotoxin and microbial-limit testing on the specific lot is recommended at the COA stage.
Primary buyer fit: academic and contract research laboratories.
Specifications
Batch COAs and test reports
Each picture is a low-resolution preview of a report's first page, with batch and report numbers covered. For the full, clear report, ask our sales team, naming the product and strength.
Batch COAPinealon 5 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Batch COAPinealon 10 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Third-party reportPinealon 10 mg
HPLC purity · MS identity
Third-party laboratory, Tianjin, China
Full, clear copy from sales
Independent test fails? Full refund. How it works
Browse all COAs and reportsRegulatory note
Research-use-only reference material; not for human or veterinary use.
Selected literature
Frequently asked questions
The only route with a real research track record for the EDR tripeptide is subcutaneous, commonly cited as a 5 mg once-daily dose over a 20-day cycle. A much lower oral figure appears in circulation but lacks a traceable primary source, and no intranasal or intramuscular protocol could be independently verified. Before compounding, document the intended route with its supporting primary reference and do not label a preparation for a route you cannot source. Anchoring the batch instruction to a verifiable route protects the lab from preparing material for an unsupported administration path.
Confirm the EDR tripeptide at receipt with an orthogonal check pairing an HPLC purity result against its stated limit with a mass confirmation near the roughly 418 g/mol figure, recording the three-residue sequence assignment rather than trusting the name. Verify salt form, water content, and lyophilizate appearance against the COA. Store at -20 degrees Celsius protected from light and track the assigned re-test interval. Reconstitute in isotonic saline, calculate concentration from the net-peptide assay basis, aliquot into single-use volumes, and hold frozen to limit freeze-thaw loss. Log lot, assay basis, and re-test date for traceability.
Send any vial from your order to an independent laboratory of your choice. If the report shows the product does not meet the specification on its COA — purity below the stated minimum, or an identity that does not match — share the report with our sales team and we refund that product in full.
Related peptides